Coherus BioSciences Inc Working Capital to Net Assets Ratio
Coherus BioSciences Inc working capital to net assets ratio. Coherus BioSciences Inc (CHRS) has a Working Capital to Net Assets ratio of 95.8% as of June 2026. Working capital of $58.28 Million (current assets of $133.79 Million minus current liabilities of $75.51 Million) is measured against net assets of $60.84 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Coherus BioSciences Inc's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Coherus BioSciences Inc (2012–2025)
Working capital to net assets ratio of Coherus BioSciences Inc from 2012 to 2025. This chart shows how Coherus BioSciences Inc's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 95.8%, reflecting working capital of $58.28 Million against net assets of $60.84 Million USD. See Coherus BioSciences Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Coherus BioSciences Inc Working Capital to Net Assets Ratio by Year (2012–2025)
Coherus BioSciences Inc working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Coherus BioSciences Inc from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see CHRS total asset value.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 106.3% | $64.83 Million | $61.01 Million | $206.71 Million | $141.88 Million | ▲ +150.7 pp |
| 2024 | -44.4% | $58.60 Million | $-131.99 Million | $341.58 Million | $282.98 Million | ▲ +30.0 pp |
| 2023 | -74.4% | $143.86 Million | $-193.43 Million | $475.63 Million | $331.77 Million | ▲ +102.1 pp |
| 2022 | -176.5% | $242.54 Million | $-137.42 Million | $381.23 Million | $138.69 Million | ▼ -623.7 pp |
| 2021 | 447.2% | $437.00 Million | $97.73 Million | $602.32 Million | $165.33 Million | ▲ +225.9 pp |
| 2020 | 221.3% | $621.83 Million | $280.97 Million | $767.48 Million | $145.65 Million | ▼ -25.6 pp |
| 2019 | 246.9% | $259.76 Million | $105.21 Million | $374.73 Million | $114.97 Million | ▲ +348.2 pp |
| 2018 | -101.3% | $39.09 Million | $-38.59 Million | $72.36 Million | $33.26 Million | ▼ -423.9 pp |
| 2017 | 322.6% | $98.52 Million | $30.54 Million | $126.91 Million | $28.39 Million | ▼ -31.7 pp |
| 2016 | 354.3% | $68.57 Million | $19.35 Million | $124.95 Million | $56.38 Million | ▲ +1107.8 pp |
| 2015 | -753.5% | $52.21 Million | $-6.93 Million | $158.23 Million | $106.02 Million | ▼ -901.2 pp |
| 2014 | 147.7% | $98.61 Million | $66.76 Million | $150.39 Million | $51.78 Million | ▲ +128.8 pp |
| 2013 | 18.9% | $-8.02 Million | $-42.38 Million | $45.68 Million | $53.70 Million | ▼ -128.4 pp |
| 2012 | 147.4% | $13.55 Million | $9.19 Million | $24.80 Million | $11.25 Million | — |